<DOC>
	<DOC>NCT00159289</DOC>
	<brief_summary>The primary aim of this study is to investigate the effects of inhaled lipopolysaccharide endotoxin (LPS) on bronchial and alveolar exhaled nitric oxide (NO) and NO metabolites and other inflammatory markers and mediators in exhaled breath condensate, induced sputum, nasal lavage and mouthwash fluid in healthy non-smokers and current smokers, including patients with chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Healthy nonsmokers: normal spirometry (forced expiratory volume in 1 second [FEV1] more than or equal to 90% predicted) and normal exhaled NO (between 8 and 24 ppb; flow 50 ml/s) 0: At risk (current or exsmokers): normal spirometry, with or without chronic symptoms (cough, sputum production) III: Mildmoderate COPD FEV1 reversibility of &lt; 15% after inhaled beta2agonists FEV1/forced vital capacity (FVC) &lt; 70% predicted FEV1 between greater than or equal to 50% and less than 80% With or without chronic symptoms (cough, sputum production) Able to comprehend and grant a written informed consent Concomitant use or pretreatment within the last 4 weeks with oral steroids Respiratory infection within 4 weeks prior to entry into the trial Females who are pregnant or lactating History of current or past drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Mild to moderate Chronic Obstructive Pulmonary Disease (COPD)</keyword>
	<keyword>Volunteers (healthy non-smokers)</keyword>
	<keyword>Volunteers (current or ex-smokers)</keyword>
</DOC>